"rationale","instanceType","uuid:ID","id","versionIdentifier"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","8d9e5b49-7c60-49ca-884b-e14cba26407c","StudyVersion_1","2"
